As such, the benefits of FGF23-driven volume regulation to balance phosphate levels in CKD come at the cost of progressive kidney damage, which reflects an unfavorable trade-off, i.e., the cost is higher than the benefit (Fig. 2). Here, FGF23 is linked to chronic kidney disease.